Cellectis Sa Stock Analysis

Cellectis Stock Analysis Notes

About 14.0% of the company shares are held by institutions such as insurance companies. The book value of Cellectis was currently reported as 1.39. The company recorded a loss per share of 0.33. Cellectis SA had not issued any dividends in recent years. Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 294 people. For more info on Cellectis SA please contact Andre Choulika at 33 1 81 69 16 00 or go to https://www.cellectis.com.

Cellectis SA Investment Alerts

Cellectis Largest EPS Surprises

View All Earnings Estimates

Cellectis Environmental, Social, and Governance (ESG) Scores

Cellectis Thematic Classifications

Cellectis Stock Institutional Investors

Note, although Cellectis' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cellectis Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 360.55 M.

Cellectis Profitablity

The company has Profit Margin (PM) of (0.43) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.22 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.22.

Management Efficiency

Cellectis SA has return on total asset (ROA) of (0.0447) % which means that it has lost $0.0447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3075) %, meaning that it created substantial loss on money invested by shareholders. Cellectis' management efficiency ratios could be used to measure how well Cellectis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.09 in 2026. Return On Capital Employed is likely to drop to -0.26 in 2026. At this time, Cellectis' Non Currrent Assets Other are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 243.1 M in 2026, whereas Non Current Assets Total are likely to drop slightly above 58.8 M in 2026.

Technical Drivers

As of the 5th of February, Cellectis shows the Downside Deviation of 4.68, risk adjusted performance of 0.0308, and Mean Deviation of 3.75. Cellectis SA technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cellectis SA downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Cellectis SA is priced correctly, providing market reflects its regular price of 3.54 per share. Given that Cellectis has jensen alpha of 0.1113, we suggest you to validate Cellectis SA's prevailing market performance to make sure the company can sustain itself at a future point.

Cellectis SA Price Movement Analysis

Cellectis Outstanding Bonds

Cellectis Predictive Daily Indicators

Cellectis Forecast Models

Cellectis' time-series forecasting models are one of many Cellectis' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cellectis' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Cellectis SA Debt to Cash Allocation

Cellectis SA currently holds 91.46 M in liabilities with Debt to Equity (D/E) ratio of 0.52, which is about average as compared to similar companies. Cellectis SA has a current ratio of 3.11, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Cellectis' use of debt, we should always consider it together with its cash and equity.

Cellectis Total Assets Over Time

Cellectis Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Cellectis uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Cellectis Debt Ratio

23.0

It appears most of the Cellectis' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Cellectis' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Cellectis, which in turn will lower the firm's financial flexibility.

Cellectis Corporate Bonds Issued

Cellectis Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cellectis prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cellectis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cellectis. By using and applying Cellectis Stock analysis, traders can create a robust methodology for identifying Cellectis entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cellectis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cellectis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Cellectis SA stock analysis indicators help investors evaluate how Cellectis stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cellectis shares will generate the highest return on investment. By understating and applying Cellectis stock analysis, traders can identify Cellectis position entry and exit signals to maximize returns.

When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.